Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 26

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class

Carson, Culley C.·2007·Urologic Clinics of North America
DOI 10.1016/j.ucl.2007.08.013
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ucl.2007.08.013

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 52

  1. Carson, 2005, Phosphodiesterase type 5 inhibitors for erectile dysfunction, BJU Int, 96, 257, 10.1111/j.1464-410X.2005.05614.x · DOI
  2. Bella, 2007, Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications, Eur Urol, 52, 990, 10.1016/j.eururo.2007.06.048 · DOI
  3. Lue, 2000, Erectile dysfunction, N Engl J Med, 342, 1802, 10.1056/NEJM200006153422407 · DOI · Paper page
  4. Butcher, 1962, Adenosine 3′,5′-phosphate in biological materials. I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine, J Biol Chem, 237, 1244, 10.1016/S0021-9258(18)60316-3 · DOI · Paper page
  5. Sutherland, 1958, Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles, J Biol Chem, 232, 1077, 10.1016/S0021-9258(19)77423-7 · DOI · Paper page
  6. Corbin, 2004, Mechanisms of action of PDE5 inhibition in erectile dysfunction, Int J Impot Res, 16, S4, 10.1038/sj.ijir.3901205 · DOI
  7. Francis, 2001, Cyclic nucleotide phosphodiesterases: relating structure and function, Prog Nucleic Acid Res Mol Biol, 65, 1
  8. Carson, 2004, The efficacy and safety of tadalafil: an update, BJU Int, 93, 1276, 10.1111/j.1464-410X.2004.04819.x · DOI
  9. Gresser, 2002, Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil—review of the literature, Eur J Med Res, 7, 435
  10. Hellstrom, 2003, Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones, J Urol, 170, 887, 10.1097/01.ju.0000081053.97792.da · DOI · Paper page
  11. Padma-Nathan, 2001, Oral drug therapy for erectile dysfunction, Urol Clin North Am, 28, 321, 10.1016/S0094-0143(05)70141-5 · DOI · Paper page
  12. Rajagopalan, 2003, Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, J Clin Pharmacol, 43, 260, 10.1177/0091270002250604 · DOI · Paper page
  13. Corbin, 2004, Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5), Neurochem Int, 45, 859, 10.1016/j.neuint.2004.03.016 · DOI
  14. Brock, 2002, Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses, J Urol, 168, 1332, 10.1016/S0022-5347(05)64442-4 · DOI · Paper page
  15. Porst, 2003, Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial, Urology, 62, 121, 10.1016/S0090-4295(03)00359-5 · DOI · Paper page
  16. Carson CC, 2002, Sildenafil citrate treatment for erectile dysfunction: rate of adverse events decreases with time, J Urol, 167, 167
  17. Stief, 2004, Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction, Int J Clin Pract, 58, 230, 10.1111/j.1368-5031.2004.00128.x · DOI
  18. Kostis, 2005, Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference), Am J Cardiol, 96, 313, 10.1016/j.amjcard.2005.03.065 · DOI
  19. Carson, 2005, Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors, Am J Cardiol, 96, 37M, 10.1016/j.amjcard.2005.07.010 · DOI
  20. Sussman, 2004, Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors, J Am Osteopath Assoc, 104, S11
  21. Ishikura, 2000, Effects of sildenafil citrate (Viagra) combined with nitrate on the heart, Circulation, 102, 2516, 10.1161/01.CIR.102.20.2516 · DOI
  22. Webb, 2000, Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina, J Am Coll Cardiol, 36, 25, 10.1016/S0735-1097(00)00705-1 · DOI
  23. Kloner, 2003, Time course of the interaction between tadalafil and nitrates, J Am Coll Cardiol, 42, 1855, 10.1016/j.jacc.2003.09.023 · DOI
  24. Padma-Nathan, 1998, Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group, Int J Clin Pract, 52, 375, 10.1111/j.1742-1241.1998.tb08886.x · DOI
  25. Hellstrom, 2002, Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial, J Androl, 23, 763, 10.1002/j.1939-4640.2002.tb02332.x · DOI · Paper page
  26. Jetter, 2002, Effects of grapefruit juice on the pharmacokinetics of sildenafil, Clin Pharmacol Ther, 71, 21, 10.1067/mcp.2002.121236 · DOI
  27. Leslie, 2004, No adverse hemodynamic interaction between sildenafil and red wine, Clin Pharmacol Ther, 76, 365, 10.1016/j.clpt.2004.07.005 · DOI
  28. Carson, 2003, Long-term use of sildenafil, Expert Opin Pharmacother, 4, 397, 10.1517/14656566.4.3.397 · DOI
  29. Hellstrom, 2003, Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial, Urology, 61, 8, 10.1016/S0090-4295(03)00115-8 · DOI
  30. Carson, 2005, Efficacy and safety of tadalafil in men with severe erectile dysfunction in tertiary care academic centers, Curr Urol Rep, 6, 437, 10.1007/s11934-005-0038-x · DOI
  31. Carson, 2005, Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers, Urology, 65, 353, 10.1016/j.urology.2004.09.056 · DOI
  32. Saenz de Tejada, 2002, Effects of tadalafil on erectile dysfunction in men with diabetes, Diabetes Care, 25, 2159, 10.2337/diacare.25.12.2159 · DOI · Paper page
  33. Fonseca, 2004, Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials, Diabetologia, 47, 1914, 10.1007/s00125-004-1549-6 · DOI · Paper page
  34. Goldstein, 2003, Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study, Diabetes Care, 26, 777, 10.2337/diacare.26.3.777 · DOI
  35. Rendell, 1999, Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group, JAMA, 281, 421, 10.1001/jama.281.5.421 · DOI
  36. Lowentritt, 1999, Sildenafil citrate after radical retropubic prostatectomy, J Urol, 162, 1614, 10.1016/S0022-5347(05)68179-7 · DOI
  37. Montorsi, 2004, Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial, J Urol, 172, 1036, 10.1097/01.ju.0000136448.71773.2b · DOI · Paper page
  38. Hong, 1999, Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP), Int J Impot Res, 11, S15, 10.1038/sj.ijir.3900466 · DOI
  39. Brock, 2003, Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy, J Urol, 170, 1278, 10.1097/01.ju.0000086947.00547.49 · DOI
  40. McCullough, 2003, An update on the PDE-5 inhibitors (PDE-5i), J Androl, 24, S52
  41. Sairam, 2002, Sildenafil influences lower urinary tract symptoms, BJU Int, 90, 836, 10.1046/j.1464-410X.2002.03040.x · DOI · Paper page
  42. McVary, 2007, Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial, J Urol, 177, 1071, 10.1016/j.juro.2006.10.055 · DOI
  43. McVary, 2007, Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia, J Urol, 177, 1401, 10.1016/j.juro.2006.11.037 · DOI · Paper page
  44. Padma-Nathan, 2003, Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial, Urology, 62, 400, 10.1016/S0090-4295(03)00567-3 · DOI
  45. Carson, 2005, Erectile dysfunction and treatment of carcinoma of the prostate, Curr Urol Rep, 6, 461, 10.1007/s11934-005-0042-1 · DOI
  46. Bates, 2007, Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema, Curr Opin Investig Drugs, 8, 226
  47. Krymskaya, 2007, Phosphodiesterases regulate airway smooth muscle function in health and disease, Curr Top Dev Biol, 79, 61, 10.1016/S0070-2153(06)79003-2 · DOI
  48. Kane, 2006, Present and future treatment strategies for pulmonary arterial hypertension: focus on phosphodiesterase-5 inhibitors, Treat Respir Med, 5, 271, 10.2165/00151829-200605040-00005 · DOI
  49. Reffelmann, 2006, Cardiovascular effects of phosphodiesterase 5 inhibitors, Curr Pharm Des, 12, 3485, 10.2174/138161206778343073 · DOI
  50. Gratzke, 2007, In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach, Urol Res, 35, 49, 10.1007/s00240-006-0073-1 · DOI
  51. Salem, 2006, Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction, Curr Opin Investig Drugs, 7, 661
  52. Bayes, 2006, Gateways to clinical trials, Methods Find Exp Clin Pharmacol, 28, 719

Cited by

Metadata

Authors
Carson, C. C.
Venue
Urologic Clinics of North America
Publisher
Elsevier BV
Published
2007-11
Volume
34
Issue
4
Pages
507-515
ISSN
0094-0143
DOI
10.1016/j.ucl.2007.08.013
Cited by
26
References
3
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.